肺癌筛查中检出肺外恶性肿瘤:一家三级医院5年分析
该回顾性研究分析了2014年6月至2019年12月间4160例患者共7414次低剂量CT肺癌筛查,共225例患者报告241个肺外病变,检出20个肺外恶性肿瘤,患病率0.48%。其中65%(13/20)为早期癌,未观察到癌症特异性死亡。恶性肿瘤预测值因器官而异(P=.03),胸壁和腋窝最高(36.4%),骨次之(25%)。
要点
- 肺癌筛查低剂量CT可检出肺外恶性肿瘤,患病率0.48%(20/4160)。
- 胸壁和腋窝病变的恶性预测值最高(36.4%),骨病变为25%。
- 65%(13/20)的肺外恶性肿瘤为早期,未观察到癌症特异性死亡。
临床应用与阅片要点
- 根据Medicare报销标准,诊断一个肺外恶性肿瘤的平均费用为$1,316.03(每名参与者$6.33,每个不确定偶发病变$109.21)。
- 大多数患者(203/225,90.2%)没有与诊断检查相关的自付费用;有自付费用者的中位费用为$160.60(范围$75-$606.76)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aims of this study were to determine the prevalence and outcomes of extrapulmonary malignancies identified on lung cancer screening (LCS) and to determine the cost associated with the investigation of these lesions.
METHODS: This retrospective study included 7,414 low-dose CT studies performed between June 2014 and December 2019 on 4,160 patients as part of an established LCS program. Patients with indeterminate extrapulmonary lesions were identified, and the diagnostic workup, management, and outcomes of the lesions were determined. Costs related to diagnostic evaluation were estimated using 2020 total facility relative value units and the 2020 Medicare conversion factor. Out-of-pocket costs were extracted from billing records.
RESULTS: There were 20 extrapulmonary malignancies among 241 reported lesions in 225 patients (mean age, 66.1 ± 6.4 years; 109 men, 116 women). The prevalence of extrapulmonary malignancy was 20 of 4,160 (0.48%). Early-stage cancers were detected in 13 of 20 (65%). No cancer-specific mortality was observed. The predictive value for malignancy varied by organ (P = .03) and was highest in the chest wall and axilla (36.4%), followed by bone (25%). The average cost on the basis of Medicare reimbursement for diagnosis of an extrapulmonary malignancy on LCS was $1,316.03 ($6.33 per participant and $109.21 per indeterminate incidental lesion). Most patients (203 of 225 [90.2%]) did not have out-of-pocket costs related to diagnostic workup. In those who did, the median cost was $160.60 (range, $75-$606.76).
CONCLUSIONS: Low-dose CT for LCS detects extrapulmonary malignancy with high predictive value for certain locations. There is cost associated in the workup related to these incidental lesions, but most malignancies are detected at early stages and have good outcomes.
引用
- Chintanapakdee W, Mendoza DP, Zhang EW, et al. Detection of Extrapulmonary Malignancy During Lung Cancer Screening: 5-Year Analysis at a Tertiary Hospital. J Am Coll Radiol. 2020. PMID: 33058791. doi:10.1016/j.jacr.2020.09.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。